References
Small Animal Review

Abstract
Summary: Allergic dermatitis in dogs can be managed using a range of medical therapies including glucocorticoids, ciclosporin, oclacitinib, loviketmab and immunotherapy. Oclacitinib inhibits janus-kinases leading to depressed function of proinflammatory cytokines. Some cytokines protect against tumour development. Oclacitinib may hinder cell proliferation, differentiation, migration, apoptosis and survival. Oclacitinib's impact in dogs who have neoplasia is unclear. The study discussed here has assessed the risk of neoplasia in dogs treated over a long period with oclacitinib.
Allergic or hypersensitivity dermatitis is not uncommonly described in dogs, and may be managed using a range of medical therapies including glucocorticoids, ciclosporin, oclacitinib (Apoquel; Zoetis), loviketmab (Cytopoint; Zoetis) and immunotherapy. In humans, long-term treatment with ruxolitinib, a related compound, has been associated with an increased risk of developing epidermal tumours (basal cell tumours and squamous cell carcinomas). In contrast, the use of tofacitinib, another inhibitor of janus-kinases (JAKs), has not been associated with significant adverse effects. The impact of using oclacitinib in dogs who have neoplasia is unclear, so a study assessing the risk of neoplasia in dogs treated over a long period with oclacitinib (Lancellotti et al, 2020) is welcome.
The study, published in JAVMA, was a retrospective analysis of data from dogs receiving treatment for allergic dermatitis with or without oclacitinib. The study population of dogs with allergic dermatitis comprised 339 dogs that had received oclacitinib for more than 6 months and 321 dogs that had never been prescribed the drug. In the group exposed to oclacitinib treatment, times ranged from 6–58 months and the sum total follow-up duration was 1105.6 patient years. The unexposed group had been treated for 3–107 months and the sum total follow-up duration was 1106.5 patient years. Overall, the cumulative incidence of skin masses, including all masses irrespective of diagnosis, did not differ significantly between the two groups (56.6% in the exposed and 58.3% in the non-exposed dogs) and the overall incidence rate for mass development did not vary (174 new cases/1000 patient years in the exposed dogs and 169 new cases/1000 patient years in the control dogs).
Register now to continue reading
Thank you for visiting UK-VET Companion Animal and reading some of our peer-reviewed content for veterinary professionals. To continue reading this article, please register today.